TIPE2 mRNA overexpression correlates with TNM staging in renal cell carcinoma tissues

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 571-575

  Zhang, Zongliang ^a,b   Qi, Haiyan ^b   Hou, Sichuan ^b   Jin, Xunbo ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Myxoma resistance protein 1; Renal cell carcinoma; TNM staging; Tumor necrosis factor induced protein 8 like 2; Type I interferon

Indexed keywords

MESSENGER RNA; MYXOMA RESISTANCE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 8 LIKE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UPREGULATION;

EID: 84879480697     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1388     Document Type: Article

References (30)

1. Ku JH, Park YH, Myung JK, Moon KC, Kwak C and Kim HH: Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation. Urol Oncol 29: 731-737, 2011.
2. Cavalcanti E, Gigante M, Mancini V, et al: JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. J Biomed Biotechnol 2010: 935764, 2010.
3. Atkins D, Ferrone S, Schmahl GE, et al: Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171: 885-889, 2004.
4. Li D, Song L, Fan Y, et al: Down-regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 133: 422-427, 2009.
5. Sun H, Gong S, Carmody RJ, et al: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133: 415-426, 2008.
6. Luan YY, Yao YM, Zhang L, et al: Expression of tumor necrosis factor-α induced protein 8 like-2 contributes to the immunosuppressive property of CD4(+)CD25(+) regulatory T cells in mice. Mol Immunol 49: 219-226, 2011.
7. Kumar D, Whiteside TL and Kasid U: Identification of a novel tumor necrosis factor-alpha-inducible gene SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1 beta-converting enzyme-inhibitory protein. J Biol Chem 275: 2973-2978, 2000.
8. Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, tenCate JW and Pannekoek H: Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 93: 3418-3431, 1999.
9. You Z, Ouyang H, Lopatin D, Polver PJ and Wang CY: Nuclear factor-kappa B inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem 276: 26398-26404, 2001.
10. Zhang HG, Hyde K, Page GP, et al: Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum 50: 420-431, 2004.
11. Zhang S, Zhang Y, Wei X, et al: Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta 1802: 1078-1086, 2010.
12. Zhang C, Chakravarty D, Sakabe I, et al: Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther 13: 947-955, 2006.
13. Lee PY, Li Y, Richards HB, et al: Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 56: 3759-3769, 2007.
14. Ebele JN, Sauter G, Epstein JI and Sesterhenn IA (eds): Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC, Lyon, 2004.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, TrottiAIII (eds): AJCC Cancer Staging Manual. 7th edition. Springer, New York, 2010.
16. Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I and Kasid U: Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene 23: 612-616, 2004.
17. Patel S, Wang FH, Whiteside TL and Kasid U: Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol 33: 197-203, 1997.
18. Yoshinaga-Hirabayashi T and Yoneda Y: Expression of SCC in ovarian granulosa cells and cultured cells, induced rapid structural changes in mitochondria. Ital J Anat Embryol 106 (2Suppl 1): 51-57, 2001.
19. Dong QZ, Zhao Y, Liu Y, Wang Y, et al: Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci 101: 1562-1569, 2010.
20. Zhang X, Wang J, Fan C, et al: Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol 16: 89-90, 2009.
21. Gus-Brautbar Y, Johnson D, Zhang L, et al: The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 45: 610-618, 2012.
22. Stark GR, Kerr IM, Williams BR, Silverman RH and SchreiberRD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998.
23. Pascual V, Farkas L and Banchereau J: Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18: 676-682; 2006.
24. Koutouzov S, Mathian A and Dalloul A: Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 5: 554-562, 2006.
25. Hawiger D, Inaba K, Dorsett Y, et al: Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779, 2001.
26. Feng X, Wu H, Grossman JM, et al: Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2951-2962, 2006.
27. Zhuang H, Narain S, Sobel E, et al: Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. Clin Immunol 117: 238-250, 2005.
28. Colonna M: TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol 37: 306-309, 2007.
29. Honda K, Yanai H, Negishi H, et al: IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777, 2005.
30. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV and Abba MC: MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201: 102-110, 2010.